CLEAR Outcomes prespecified analysis: RCT looking at bempedoic acid in people with and without diabetes
In this medfyle
Lowering cholesterol reduces CV risk. Statins are the first-line option, but they may increase HbA1c and new-onset diabetes. A new prespecified analysis of the CLEAR Outcomes trial looks at bempedoic acid – a new agent for high cholesterol.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, Nissen SE; CLEAR OUTCOMES Committees and Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024 Jan;12(1):19-28. doi: 10.1016/S2213-8587(23)00316-9. Epub 2023 Dec 4. PMID: 38061370.
The summary content was prepared by Medfyle, and reviewed by Marco Comoglio, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
